HRP20171739T1 - Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina - Google Patents
Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina Download PDFInfo
- Publication number
- HRP20171739T1 HRP20171739T1 HRP20171739TT HRP20171739T HRP20171739T1 HR P20171739 T1 HRP20171739 T1 HR P20171739T1 HR P20171739T T HRP20171739T T HR P20171739TT HR P20171739 T HRP20171739 T HR P20171739T HR P20171739 T1 HRP20171739 T1 HR P20171739T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- therapeutically effective
- cyclobenzaprine
- effective amount
- use according
- Prior art date
Links
- 208000028173 post-traumatic stress disease Diseases 0.000 title claims 9
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 title claims 7
- 229960003572 cyclobenzaprine Drugs 0.000 title claims 7
- 208000024891 symptom Diseases 0.000 title claims 6
- 239000000203 mixture Substances 0.000 title claims 4
- 238000000034 method Methods 0.000 title claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 238000009472 formulation Methods 0.000 claims 3
- 239000010409 thin film Substances 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 238000007596 consolidation process Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (8)
1. Farmaceutska kompozicija koja sadrži ciklobenzaprin u terapeutski efikasnoj količini i terapeutski efikasan nosač, za upotrebu u postupku za liječenje razvoja simptoma posttraumatskog stresnog poremećaja (PTSD), ili pojave simptoma PTSD, ili konsolidacije simptoma PTSD, ili održavanja simptoma PTSD koji se javlja nakon traumatskog događaja, koji obuhvaća primjenu kod čovjeka kome je takvo liječenje potrebno navedene farmaceutske kompozicije, pri čemu takvo liječenje otklanja ili poboljšava simptom PTSD, naznačena time što je terapeutski efikasna količina primijenjenog ciklobenzaprina između 0.5 mg i 50 mg/dan.
2. Farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 1, naznačena time što je terapeutski efikasna količina primijenjenog ciklobenzaprina manja od 10 mg/dan.
3. Farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 1, naznačena time što se farmaceutska kompozicija primjenjuje kao tableta koja se otapa oralno ili kao formulacija tankog filma.
4. Farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 1, koja dodatno sadrži lijek odabran iz grupe koja se sastoji od antagonista alfa-1-adrenergičkog receptora, beta-adrenergičkog antagonista, antikonvulzanta, selijektivnog inhibitora ponovnog preuzimanja serotonina ili inhibitora ponovnog preuzimanja serotonina i norepinefrina.
5. Farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 4, naznačena time što je farmaceutska kompozicija tableta koja se otapa oralno ili formulacija tankog filma.
6. Farmaceutska kompozicija koja sadrži ciklobenzaprin u terapeutski efikasnoj količini i terapeutski efikasan nosač za upotrebu u postupku za liječenje poremećaja sna ili poremećaja koji nije povezan sa snom udruženog sa posttraumatskim stresnim poremećajem (PTSD), koji obuhvaća primjenu kod čovjeka kome je takvo liječenje potrebno navedene farmaceutske kompozicije, pri čemu takvo liječenje poboljšava ili otklanja poremećaj koji nije povezan sa snom, naznačena time što je terapeutski efikasna količina primijenjenog ciklobenzaprina između 0.5 mg i 50 mg/dan.
7. Farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 6, naznačena time što je terapeutski efikasna količina primijenjenog ciklobenzaprina manja od 10 mg/dan.
8. Farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 6, naznačena time što se farmaceutska kompozicija primjenjuje kao tableta koja se otapa oralno ili kao formulacija tankog filma.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28166109P | 2009-11-20 | 2009-11-20 | |
EP10831895.7A EP2501234B1 (en) | 2009-11-20 | 2010-11-16 | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
PCT/US2010/002979 WO2011062614A1 (en) | 2009-11-20 | 2010-11-16 | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20171739T1 true HRP20171739T1 (hr) | 2018-03-09 |
Family
ID=44059887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171739TT HRP20171739T1 (hr) | 2009-11-20 | 2017-11-13 | Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina |
Country Status (14)
Country | Link |
---|---|
US (2) | US9918948B2 (hr) |
EP (1) | EP2501234B1 (hr) |
CY (1) | CY1119698T1 (hr) |
DK (1) | DK2501234T3 (hr) |
ES (1) | ES2649022T3 (hr) |
HR (1) | HRP20171739T1 (hr) |
HU (1) | HUE037281T2 (hr) |
LT (1) | LT2501234T (hr) |
NO (1) | NO2501234T3 (hr) |
PL (1) | PL2501234T3 (hr) |
PT (1) | PT2501234T (hr) |
RS (1) | RS56634B1 (hr) |
SI (1) | SI2501234T1 (hr) |
WO (1) | WO2011062614A1 (hr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011062614A1 (en) | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
RS63822B1 (sr) * | 2012-06-15 | 2023-01-31 | Tonix Pharma Holdings Ltd | Kompozicije i postupci za transmukoznu apsorpciju |
CA2904812C (en) | 2013-03-15 | 2021-07-20 | Tonix Pharmaceuticals, Inc. | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
CN114736305B (zh) | 2014-01-10 | 2023-05-05 | 比奥贝拉蒂治疗公司 | 因子viii嵌合蛋白及其用途 |
WO2016044796A1 (en) | 2014-09-18 | 2016-03-24 | Seth Lederman | Eutectic formulations of cyclobenzaprine hydrochloride |
CA3083341A1 (en) | 2017-12-11 | 2019-06-20 | Tonix Pharma Holdings Limited | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
JP2021534192A (ja) * | 2018-08-20 | 2021-12-09 | トニックス ファーマ ホールディングス リミテッド | 急性ストレス障害および外傷後ストレス障害を処置する方法 |
US20220016074A1 (en) | 2018-11-21 | 2022-01-20 | Rosemont Pharmaceuticals Limited | Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability |
JP7088153B2 (ja) * | 2019-09-19 | 2022-06-21 | カシオ計算機株式会社 | Cap(周期性脳波活動)検出装置、cap(周期性脳波活動)検出方法及びプログラム |
US20210315841A1 (en) * | 2020-04-08 | 2021-10-14 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for sexual dysfunction |
JP2023554597A (ja) | 2020-11-20 | 2023-12-28 | トニックス ファーマシューティカルズ ホールディング コーポレイション | アルコール使用障害のためのシクロベンザプリン処置 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968507A (en) | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
SG47101A1 (en) | 1992-07-31 | 1998-03-20 | Us Bioscience | Crystalline amifostine compositions and methods for the preparation and use of same |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
CN1245156C (zh) | 1993-02-22 | 2006-03-15 | 美国生物科学有限公司 | 用于体内传送生物制品的方法及用于该方法的组合物 |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US20030077227A1 (en) | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
WO1999018937A1 (en) | 1997-10-16 | 1999-04-22 | Merck & Co., Inc. | New cyclobenzaprine composition |
PT1077683E (pt) | 1998-05-14 | 2003-04-30 | Alza Corp | Terapia anti-depressiva |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
WO2001012174A1 (en) | 1999-08-13 | 2001-02-22 | Vela Pharmaceuticals Inc. | Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
JP2003506484A (ja) | 1999-08-13 | 2003-02-18 | ベラ・ファーマシューティカルズ・インコーポレイテッド | 非常に低用量のシクロベンザプリンを使用する睡眠障害の処置または予防するための組成物使用 |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
WO2001089476A1 (en) | 2000-05-19 | 2001-11-29 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
WO2003039525A1 (en) | 2001-11-05 | 2003-05-15 | Krele Pharmaceuticals Llc | Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism |
US7105486B2 (en) | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
US7700561B2 (en) | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
US7223735B2 (en) | 2003-05-29 | 2007-05-29 | New River Pharmaceuticals Inc. | Abuse resistant lysine amphetamine compounds |
US7659253B2 (en) | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
CA2503381A1 (en) * | 2002-10-25 | 2004-05-13 | Collegium Pharmaceutical, Inc. | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
TR200502189T1 (tr) | 2002-12-09 | 2007-01-22 | American Bioscience, Inc. | Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler. |
EP1685115A1 (en) | 2003-11-03 | 2006-08-02 | Warner-Lambert Company LLC | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
US20050143350A1 (en) | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
JP2007516259A (ja) | 2003-12-09 | 2007-06-21 | メッドクリスタルフォームズ、エルエルシー | 活性剤との混合相共結晶の調製方法 |
US7658945B2 (en) | 2004-02-17 | 2010-02-09 | Transcept Pharmaceuticals, Inc. | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
US8216610B2 (en) | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
US7532935B2 (en) | 2005-07-29 | 2009-05-12 | Cyberonics, Inc. | Selective neurostimulation for treating mood disorders |
US7994220B2 (en) | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
US20090069267A1 (en) * | 2006-01-17 | 2009-03-12 | Abrams Daniel J | Central administration of stable formulations of therapeutic agents for cns conditions |
US20080146672A1 (en) | 2006-12-08 | 2008-06-19 | Denton Marcia Marye | Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue |
AU2008268667A1 (en) * | 2007-06-22 | 2008-12-31 | Merck & Co., Inc. | 6.5-pyrrolopiperidine tachykinin receptor antagonists |
US20090054403A1 (en) * | 2007-07-23 | 2009-02-26 | Synosia Therapeutics | Treatment of Post-Traumatic Stress Disorder |
US20090060983A1 (en) | 2007-08-30 | 2009-03-05 | Bunick Frank J | Method And Composition For Making An Orally Disintegrating Dosage Form |
HUE043897T2 (hu) | 2007-09-25 | 2019-09-30 | Solubest Ltd | Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra |
WO2009058950A2 (en) | 2007-10-30 | 2009-05-07 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide |
US20090148532A1 (en) | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
ES2620672T3 (es) | 2008-01-09 | 2017-06-29 | Charleston Laboratories, Inc. | Comprimidos de doble capa que comprenden oxicodona y prometazina |
US9314469B2 (en) | 2008-05-05 | 2016-04-19 | Tonix Pharma Holdings Limited | Method for treating neurocognitive dysfunction |
US20100266682A1 (en) | 2008-12-10 | 2010-10-21 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
EP2233134A1 (en) | 2009-03-27 | 2010-09-29 | McNeil AB | Multi-portion intra-oral dosage form with organoleptic properties |
US20100247586A1 (en) | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
US8807979B2 (en) | 2009-09-24 | 2014-08-19 | Mcneil-Ppc, Inc. | Machine for the manufacture of dosage forms utilizing radiofrequency energy |
WO2011062614A1 (en) | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
CA2809966C (en) | 2010-09-01 | 2019-01-08 | Tonix Pharmaceuticals, Inc. | Treatment for cocaine addiction |
RS63822B1 (sr) | 2012-06-15 | 2023-01-31 | Tonix Pharma Holdings Ltd | Kompozicije i postupci za transmukoznu apsorpciju |
CA2904812C (en) | 2013-03-15 | 2021-07-20 | Tonix Pharmaceuticals, Inc. | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
WO2016044796A1 (en) | 2014-09-18 | 2016-03-24 | Seth Lederman | Eutectic formulations of cyclobenzaprine hydrochloride |
-
2010
- 2010-11-16 WO PCT/US2010/002979 patent/WO2011062614A1/en active Application Filing
- 2010-11-16 LT LTEP10831895.7T patent/LT2501234T/lt unknown
- 2010-11-16 SI SI201031573T patent/SI2501234T1/en unknown
- 2010-11-16 EP EP10831895.7A patent/EP2501234B1/en not_active Revoked
- 2010-11-16 DK DK10831895.7T patent/DK2501234T3/en active
- 2010-11-16 HU HUE10831895A patent/HUE037281T2/hu unknown
- 2010-11-16 NO NO10831895A patent/NO2501234T3/no unknown
- 2010-11-16 PT PT108318957T patent/PT2501234T/pt unknown
- 2010-11-16 PL PL10831895T patent/PL2501234T3/pl unknown
- 2010-11-16 RS RS20171157A patent/RS56634B1/sr unknown
- 2010-11-16 ES ES10831895.7T patent/ES2649022T3/es active Active
- 2010-11-18 US US12/948,828 patent/US9918948B2/en active Active
-
2017
- 2017-11-13 HR HRP20171739TT patent/HRP20171739T1/hr unknown
- 2017-11-14 CY CY20171101187T patent/CY1119698T1/el unknown
-
2018
- 2018-03-08 US US15/915,688 patent/US20180193288A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DK2501234T3 (en) | 2017-12-04 |
US20180193288A1 (en) | 2018-07-12 |
EP2501234A1 (en) | 2012-09-26 |
NO2501234T3 (hr) | 2018-02-10 |
US9918948B2 (en) | 2018-03-20 |
PT2501234T (pt) | 2017-12-13 |
LT2501234T (lt) | 2017-12-11 |
EP2501234B1 (en) | 2017-09-13 |
US20110124656A1 (en) | 2011-05-26 |
ES2649022T3 (es) | 2018-01-09 |
PL2501234T3 (pl) | 2018-01-31 |
SI2501234T1 (en) | 2018-02-28 |
HUE037281T2 (hu) | 2018-08-28 |
WO2011062614A1 (en) | 2011-05-26 |
CY1119698T1 (el) | 2018-04-04 |
EP2501234A4 (en) | 2013-04-24 |
RS56634B1 (sr) | 2018-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171739T1 (hr) | Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina | |
Kennedy et al. | Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness | |
HRP20171743T1 (hr) | Sastavi i postupci za savladavanje otpornosti na tramadol | |
HRP20200600T1 (hr) | Tapentadol za sprječavanje i liječenje depresije i tjeskobe | |
HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
JP2012193216A5 (hr) | ||
HRP20180129T1 (hr) | Oralno raspadajuća čvrsta jedinica doze koja sadrži estetrol komponentu | |
JP2006104221A5 (hr) | ||
JP2015038135A5 (hr) | ||
HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
JP2015518006A5 (hr) | ||
JP2010222367A5 (hr) | ||
JP2013231087A5 (hr) | ||
JP2016540021A5 (hr) | ||
BRPI0908942A2 (pt) | Sistemas de distribuição de fármacos compreendendo fármacos fracamente básicos e ácidos orgânicos | |
JP2010522137A5 (hr) | ||
ATE494889T1 (de) | Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol | |
JP2016509030A5 (hr) | ||
JP2017526693A5 (hr) | ||
Popik et al. | Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats | |
JP2015514797A5 (hr) | ||
HRP20221344T1 (hr) | Novi pripravak acetaminofenskog spoja bez nuspojave po jetru | |
RU2008134143A (ru) | Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения |